QC
KNSA icon

Quantessence Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Quantessence Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,761
Closed -$229K – 100
2026
Q1 		$229K Buy
+4,761
New +$211K 1.12% 43
2025
Q3 		– Sell
-27,066
Closed -$749K – 249
2025
Q2 		$749K Buy
+27,066
New +$689K 0.22% 100

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Quantessence Capital's KNSA Position: Q2 2026 in Review

Quantessence Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 4,761 shares — an estimated $229K sold.

Quantessence Capital first reported a position in KNSA in Q2 2025 and held it in 2 quarters. The position peaked at $749K in Q2 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Quantessence Capital reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quantessence Capital sold 4,761 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $229K.
  • Quantessence Capital first reported a position in Kiniksa Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Quantessence Capital's Kiniksa Pharmaceuticals position peaked at $749K in Q2 2025.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Quantessence Capital's 13F filing for Q2 2026, filed 14 Aug 2026.